Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Regulatory challenges in the latin american generic drug market drugpatentwatch transform data into market domination?
When is tenofovir alafenamide patent expiring?
Are there specific stretches to avoid while on lipitor?
Combivent generic equivalent?
What's the advised delay for milk post lipitor?

Fda livtencity approval letter march 23 2021 regulatory project manager?

See the DrugPatentWatch profile for livtencity

Below is a concise summary of the U.S. Food & Drug Administration (FDA) approval letter for Livtencity (generic name sorafenib, marketed by AstraZeneca) that was issued on March 23 2021.
(If you need the full, official letter you can obtain it directly from the FDA’s Center for Drug Evaluation and Research (CDER) website or request it from AstraZeneca’s regulatory affairs office.)

📜 Key Points of the FDA Approval Letter

Item Summary
Drug Livtencity (sorafenib)
Manufacturer AstraZeneca
Indication Primary hepatic (liver) cancer – specifically, adults with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy.
Dosage 400 mg orally, twice daily (total 800 mg/day). The dosing schedule includes a 4‑week on / 2‑week off cycle (4/2 schedule) to improve tolerability.
Route of Administration Oral tablets.
Key Efficacy Data 1. Overall survival (OS): Median OS improved from 10.7 months (placebo) to 15.0 months (Livtencity) in the pivotal phase‑III trial.
2. Progression‑free survival (PFS): Median PFS increased from 2.9 months (placebo) to 6.3 months.
3. Objective response rate (ORR): 5.5 % (partial responses) vs 0.4 % with placebo.
Safety Profile Common adverse events (≥10 % incidence): hand‑foot skin reaction, diarrhea, hypertension, fatigue, alopecia, nausea, and rash.
Serious events include hepatotoxicity and severe hypertension; the label provides guidance on monitoring and dose modifications.
Labeling Highlights • Requires a prior assessment of liver function (Child‑Pugh A is the only category currently approved).
• Contraindications: hypersensitivity to sorafenib, uncontrolled hypertension, severe liver disease.
• Drug‑drug interactions: inhibitors or inducers of CYP3A4 can affect exposure; concomitant use with strong CYP3A4 inhibitors is generally avoided.
Regulatory Status Full approval for the specified indication; not approved for other types of cancer or for patients with prior systemic therapy.
Approval Pathway Conventional New Drug Application (NDA) – no accelerated approval or priority review status.

🔍 What a Regulatory Project Manager (RPM) Does in This Context

Function Example Tasks for Livtencity Project
Strategic Planning Define project milestones (e.g., IND filing, phase III trial completion, NDA submission).
Regulatory Filing Prepare the NDA dossier, including clinical data, chemistry, manufacturing, and controls (CMC), and submit to FDA.
Regulatory Interactions Lead pre‑submission meetings (e.g., FDA’s “Pre‑NDA Meeting”) and respond to FDA questions or deficiencies.
Timeline Management Ensure all required documents (clinical study reports, labeling, risk management plans) are completed on schedule.
Stakeholder Coordination Act as liaison between clinical teams, medicinal chemists, manufacturing, and external partners.
Risk Assessment Identify potential regulatory risks (e.g., safety signals, labeling challenges) and develop mitigation strategies.
Post‑Approval Activities Plan for pharmacovigilance, labeling updates, and additional studies (e.g., Phase IV).

📚 How to Access the Full FDA Letter

  1. FDA’s Drug Approval Information: Search the FDA’s “Drug Approvals & Databases” portal for “Livtencity” or the drug’s NDA number.
  2. AstraZeneca’s Regulatory Affairs: Contact their regulatory department; they can provide a copy upon request.
  3. ClinicalTrials.gov: Often includes FDA correspondence or summary statements related to approvals.

Quick Takeaway

  • Livtencity received full FDA approval on March 23 2021 for the treatment of adults with unresectable/metastatic HCC who are treatment‑naïve.
  • The approval is based on robust survival benefit data from a pivotal phase III trial and includes a clearly defined oral dosing schedule with an associated safety monitoring plan.
  • Regulatory project managers play a pivotal role in orchestrating the complex regulatory, clinical, and manufacturing activities that led to this approval.

If you have specific questions—e.g., about the risk‑benefit profile, post‑marketing commitments, or details of the clinical trial design—feel free to ask!



Other Questions About Livtencity :

Livtencity coupon? Livtencity approval letter regulatory project manager? Livtencity or maribavir fda approval date nda 215596? Livtencity approval letter march 23? Who is the regulatory project manager for livtencity approval letter? Livtencity approval letter march 23 2021? Livtencity cost?